United Therapeutics Co. (NASDAQ:UTHR) Director Sells $582,198.40 in Stock

United Therapeutics Co. (NASDAQ:UTHR) Director Christopher Causey sold 2,240 shares of United Therapeutics stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $259.91, for a total value of $582,198.40. Following the sale, the director now directly owns 4,185 shares in the company, valued at $1,087,723.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR traded down $1.89 during trading on Monday, reaching $260.51. The stock had a trading volume of 470,835 shares, compared to its average volume of 459,775. United Therapeutics Co. has a 52 week low of $204.44 and a 52 week high of $264.85. The business’s 50-day moving average price is $236.86 and its 200 day moving average price is $229.35. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.77 and a quick ratio of 3.64. The stock has a market capitalization of $11.56 billion, a PE ratio of 12.41 and a beta of 0.54.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.63 by $0.54. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The company had revenue of $677.70 million during the quarter, compared to analysts’ expectations of $620.31 million. During the same quarter in the previous year, the company posted $4.86 earnings per share. United Therapeutics’s quarterly revenue was up 33.7% compared to the same quarter last year. As a group, equities analysts predict that United Therapeutics Co. will post 23.88 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of UTHR. Rise Advisors LLC bought a new position in United Therapeutics in the 1st quarter worth approximately $32,000. GAMMA Investing LLC bought a new position in United Therapeutics in the 4th quarter worth approximately $43,000. Benjamin F. Edwards & Company Inc. raised its position in United Therapeutics by 63.6% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 117 shares during the last quarter. C M Bidwell & Associates Ltd. bought a new position in United Therapeutics in the 3rd quarter worth approximately $91,000. Finally, Janiczek Wealth Management LLC raised its position in United Therapeutics by 21.1% in the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock worth $111,000 after purchasing an additional 84 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on UTHR. HC Wainwright reissued a “buy” rating and set a $300.00 target price on shares of United Therapeutics in a research report on Thursday. StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 11th. Wells Fargo & Company lifted their price objective on United Therapeutics from $309.00 to $325.00 and gave the company an “overweight” rating in a report on Thursday, March 7th. Leerink Partnrs reaffirmed an “outperform” rating on shares of United Therapeutics in a report on Monday, February 5th. Finally, Wedbush reaffirmed an “outperform” rating and set a $308.00 price objective on shares of United Therapeutics in a report on Thursday, February 22nd. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $308.78.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.